Opportunity Information: Apply for PA 07 101
Apply for PA 07 101
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Targeting Calcium Regulatory Molecules for Arrhythmia Prevention (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.837 Cardiovascular Diseases Research.
- This funding opportunity was created on Dec 5, 2008 and posted on Dec 1, 2006.
- Applicants must submit their applications by Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) For profit organizations other than small businesses City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Public and State controlled institutions of higher education Independent school districts Public housing authorities/Indian housing authorities Private institutions of higher education State governments Special district governments.
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith based or community based organizations can apply.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Targeting Calcium Regulatory Molecules for Arrhythmia Prevention (R01) funding opportunity (PA-07-101) is a National Institutes of Health (NIH) program announcement from the National Heart, Lung, and Blood Institute (NHLBI) focused on new ways to prevent and stop cardiac arrhythmias by targeting calcium (Ca2+) regulatory molecules. The central idea is that abnormal handling of calcium inside heart cells is a major driver of many rhythm disorders, and that the field already has enough mechanistic insight into calcium-control pathways to begin translating that knowledge into concrete therapeutic strategies. Applications are expected to build directly on what is known about specific calcium regulatory molecules involved in arrhythmogenesis and use that knowledge to identify, validate, and test novel therapeutic targets intended to terminate arrhythmias, prevent them from recurring, or reduce susceptibility to them in clinically relevant settings.
A key expectation of the announcement is that projects will not stop at basic discovery. Competitive applications are expected to include preclinical testing or early clinical testing of promising therapeutic approaches, using established models that reflect human arrhythmogenic disease. In practice, this points toward studies that move beyond cell culture observations and into well-justified in vivo models, ex vivo human tissue when appropriate, or early-stage clinical investigations where feasible. The announcement also emphasizes translational readiness: applicants should show that, if the strategy works, there is a realistic path to advancing those findings into Phase I or Phase II clinical trials. That means reviewers will likely look for evidence of practical feasibility, such as a clear development plan, appropriate endpoints and biomarkers, safety considerations, and a rationale for how the intervention could be produced, delivered, and tested in people.
The mechanism of support is the NIH Research Project Grant (R01), which is the standard NIH mechanism for investigator-initiated research projects and typically supports multi-year, hypothesis-driven programs of work. NHLBI does not specify a fixed budget ceiling or number of awards in the summary information provided here, because both the size and duration of awards are intended to vary depending on the scope, complexity, and costs of the proposed research. In other words, funding decisions will be driven by the number of meritorious applications received, their scientific quality, and the appropriateness of the requested budgets and project periods for the work proposed.
From an eligibility standpoint, the opportunity is broadly accessible across many organization types. Eligible applicants include public and private institutions of higher education, nonprofit organizations (including both 501(c)(3) and non-501(c)(3) entities), for-profit organizations other than small businesses, small businesses, and a wide range of governmental entities (state, county, city/township, special district, and independent school districts), as well as public housing authorities/Indian housing authorities. Tribal governments and tribal organizations are included, including federally recognized tribal governments. The announcement also states that foreign institutions are eligible to apply, that eligible federal agencies may apply, and that faith-based and community-based organizations may apply, which further underscores the intent to encourage participation from a broad research and development community.
Administratively, the opportunity falls under the NIH discretionary grant category and is associated with the Health funding activity area, with CFDA number 93.837 (Cardiovascular Diseases Research). The posting date is listed as December 1, 2006, with multiple receipt dates for applications (meaning there were recurring submission cycles rather than a single deadline during the active period of the announcement). The archived date is October 2, 2009, indicating the specific announcement is no longer active, though similar topics may appear in newer NHLBI or NIH notices. The full announcement was historically hosted through the NIH grants guide at the provided link (PA-07-101), and NIH Office of Extramural Research (OER) web support is listed for access or linking issues.
Overall, this FOA is designed for teams that can connect mechanistic insight about calcium signaling and calcium-handling proteins to tangible anti-arrhythmic interventions, demonstrate efficacy in established disease-relevant models (and ideally in early clinical settings), and credibly outline how successful results could be advanced into early-phase clinical trials.
Frequently Asked Questions (FAQs)
What is the name and identifier of this funding opportunity?
The opportunity is titled Targeting Calcium Regulatory Molecules for Arrhythmia Prevention (R01) and is identified as PA-07-101.
Which agency and institute are offering this program announcement?
This is a National Institutes of Health (NIH) program announcement issued by the National Heart, Lung, and Blood Institute (NHLBI).
What is the main scientific focus of the announcement?
The FOA focuses on preventing and stopping cardiac arrhythmias by targeting calcium (Ca2+) regulatory molecules. It is grounded in the idea that abnormal calcium handling inside heart cells is a major driver of many rhythm disorders.
What is the central rationale behind targeting calcium regulatory molecules?
The announcement is based on the premise that the field has accumulated enough mechanistic insight into calcium-control pathways to begin translating that knowledge into practical therapeutic strategies aimed at terminating arrhythmias, preventing recurrence, or reducing susceptibility in clinically relevant settings.
What kind of projects are expected to be competitive under this FOA?
Competitive applications are expected to build directly on existing knowledge about specific calcium regulatory molecules involved in arrhythmogenesis and use that understanding to identify, validate, and test new therapeutic targets or approaches.
Does the FOA support basic research only, or does it emphasize translation?
It strongly emphasizes translation. The announcement explicitly signals that projects should not stop at basic discovery and should include testing of promising therapeutic approaches beyond early mechanistic observations.
What types of testing are expected (preclinical vs. clinical)?
The FOA expects preclinical testing and, where feasible, early clinical testing of promising approaches. The emphasis is on using established models that reflect human arrhythmogenic disease and demonstrating a credible path toward early-phase clinical development.
What kinds of models or study systems does the FOA point toward?
Based on the description provided, the FOA points toward studies that move beyond cell culture and into well-justified in vivo models, established disease-relevant models, and potentially ex vivo human tissue when appropriate, as well as early-stage clinical investigations where feasible.
What does the FOA mean by "translational readiness"?
Translational readiness refers to showing that if the strategy works, there is a realistic path to advancing the findings into Phase I or Phase II clinical trials. Reviewers are likely to look for practical feasibility elements such as an overall development plan, appropriate endpoints and biomarkers, safety considerations, and a rationale for how the intervention could be produced, delivered, and tested in people.
What is the grant mechanism used for this program announcement?
The mechanism of support is the NIH Research Project Grant (R01), commonly used for multi-year, hypothesis-driven, investigator-initiated research projects.
Is there a fixed budget cap or a fixed project period listed in the summary provided?
No. NHLBI does not specify a fixed budget ceiling or a fixed number of awards in the summary information provided. Award size and duration are intended to vary depending on the scope, complexity, and costs of the proposed research.
How will funding decisions be determined according to the description?
Funding decisions are expected to depend on the number of meritorious applications received, their scientific quality, and whether the requested budgets and project periods are appropriate for the work proposed.
What types of organizations are eligible to apply?
Eligibility is broad and includes: public and private institutions of higher education; nonprofit organizations (both 501(c)(3) and non-501(c)(3)); for-profit organizations other than small businesses; small businesses; and multiple governmental entities (state, county, city/township, special district, independent school districts), as well as public housing authorities/Indian housing authorities.
Are tribal governments and tribal organizations eligible?
Yes. The announcement includes tribal governments and tribal organizations, including federally recognized tribal governments.
Are foreign institutions eligible to apply?
Yes. The announcement states that foreign institutions are eligible to apply.
Can federal agencies apply?
Yes. The announcement indicates that eligible federal agencies may apply.
Are faith-based and community-based organizations allowed to apply?
Yes. The announcement states that faith-based and community-based organizations may apply.
What is the funding category and activity area associated with this FOA?
The opportunity falls under the NIH discretionary grant category and is associated with the Health funding activity area.
What CFDA number is associated with this opportunity?
The CFDA number provided is 93.837, labeled as Cardiovascular Diseases Research.
When was this opportunity posted, and is it still active?
The posting date is listed as December 1, 2006. The archived date is October 2, 2009, which indicates this specific announcement is no longer active.
Did the FOA have a single deadline or multiple receipt dates?
It had multiple receipt dates, meaning recurring submission cycles rather than a single deadline during the active period.
Where was the full announcement historically hosted, based on the description?
The full announcement was historically hosted through the NIH grants guide under the identifier PA-07-101.
Who is referenced for support if there are access or linking issues?
The description notes NIH Office of Extramural Research (OER) web support for access or linking issues.
What overall type of applicant team does this FOA appear to be designed for?
It is designed for teams that can connect mechanistic insight about calcium signaling and calcium-handling proteins to tangible anti-arrhythmic interventions, demonstrate efficacy in established disease-relevant models (and ideally early clinical settings), and credibly outline how successful results could be advanced into early-phase clinical trials.
Browse more opportunities from the same category: Health
Next opportunity: Elucidating Nature s Solutions to Heart, Lung, and Blood Diseases and Sleep Disorder Processes (R01)
Previous opportunity: Prioritizing Molecular Targets for Cancer Prevention with Nutritional Combinations (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 07 101
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 07 101) also looked into and applied for these:
| Funding Opportunity |
|---|
| Elucidating Nature s Solutions to Heart, Lung, and Blood Diseases and Sleep Disorder Processes (R01) Apply for PAR 07 102 Funding Number: PAR 07 102 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research Opportunities in Stuttering (R01) Apply for PA 07 124 Funding Number: PA 07 124 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Cell Lineage and Developmental Studies in Hearing and Balance (R01) Apply for PA 07 127 Funding Number: PA 07 127 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Evolution of Infectious Diseases (R01) Apply for PA 07 130 Funding Number: PA 07 130 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Community Based Participatory Research at NIMH (R01) Apply for PAR 07 133 Funding Number: PAR 07 133 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Integrating Lung Genetics and Genomics in Human Populations (R01) Apply for PA 07 135 Funding Number: PA 07 135 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Protein Interactions Governing Membrane Transport in Pulmonary Health and Disease (R01) Apply for PA 07 137 Funding Number: PA 07 137 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| The Relationship Between Hypertension and Inflammation (R01) Apply for PA 07 138 Funding Number: PA 07 138 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Oral Health of Special Needs and Older Populations (R01) Apply for PA 07 151 Funding Number: PA 07 151 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Early Identification and Treatment of Mental Disorders in Children and Adolescents (R01) Apply for PA 07 158 Funding Number: PA 07 158 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Temporomandibular Joint and Muscle Disorders Pathophysiological Mechanisms Linking Comorbid Conditions (R01) Apply for PA 07 150 Funding Number: PA 07 150 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Research on Mental Illnesses in Older Adults (R01) Apply for PA 07 163 Funding Number: PA 07 163 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research on Psychopathology In Intellectual Disabilities (Mental Retardation) (R01) Apply for PA 07 162 Funding Number: PA 07 162 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Epidemiological and Behavioral Research in Oral Health (R01) Apply for PA 07 169 Funding Number: PA 07 169 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Studies of Bisphosphonate Therapy and Osteonecrosis of the Jaws (R01) Apply for PA 07 185 Funding Number: PA 07 185 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Epidemiological Research on Disorders of Hearing, Balance, Smell, Taste, Voice, Speech, and Language (R01) Apply for PA 07 251 Funding Number: PA 07 251 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Proteomics in Auditory Developmental and Disease Processes (R01) Apply for PA 07 252 Funding Number: PA 07 252 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Immunology of Biofilms (R01) Apply for PA 07 288 Funding Number: PA 07 288 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Small Grant Program (R03) Apply for PAR 07 287 Funding Number: PAR 07 287 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Advances in Polycystic Kidney Disease (R01) Apply for PA 07 293 Funding Number: PA 07 293 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants

Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 07 101", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.
